Akari Therapeutics PLC (NAS:AKTX)
$ 1.95 0.09 (4.84%) Market Cap: 15.45 Mil Enterprise Value: 14.14 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 32/100

Akari Therapeutics PLC at Emerging Growth Conference (Virtual) Transcript

Oct 04, 2023 / 03:25PM GMT
Release Date Price: $3.64 (-5.21%)
Ana Berry
Berry Media - Media

Welcome back, everyone. Next, we have Akari Therapeutics. Trades on the Nasdaq under the symbol AKTX. It's a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Please welcome its CEO, Rachelle Jacques. Nice to see you, Rachelle.

Rachelle Jacques
Akari Therapeutics, plc - President & CEO

Thanks, Ana. Welcome, everybody. As Ana said, I'm Rachelle Jacques, CEO of Akari Therapeutics. Really happy to be here with you today. Today, I will be making some forward-looking statements. Please be advised.

At Akari, we are a late-stage biotech company. We were formed in 2015, focused on our lead asset, nomacopan, which is a novel inhibitor of both complement C5 and leukotriene B4. So this is really to target proinflammatory pathways, and we believe will have application in a variety of autoimmune and inflammatory diseases. So broad potential here as we're looking at various applications. It's also important in biologics to have flexibility in the way that you treat patients with the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot